Related Experiment Videos
Immunomanipulative strategies for the control of human papillomavirus associated cervical disease
1Sir Albert Sakzewski Virus Research Centre, Royal Children's Hospital, Herston, Queensland, Australia. r.tindle@mailbox.uq.edu.au
Abstract:
Three vaccine strategies that target human papillomavirus (HPV) are likely to be effective in the control of HPV-associated preneoplastic and neoplastic lesions of the uterine cervix. 1. Immunotherapy for HPV-associated cervical cancer targeted at two nonstructural PV proteins expressed in cancer cells (E6 and E7). 2. Vaccines against existing HPV infection and early premalignant lesions targeted at early viral proteins expressed in suprabasal stem cells of infected anogenital epithelium. 3. Prophylactic vaccines to prevent HPV infection involving immunization with genetically engineered virus-like particles to elicit neutralizing antibody. Strategies 1 and 2 will need to evoke cytotoxic T-cell (CTL) mediated responses.
Insights
Three human papillomavirus (HPV) vaccine strategies show promise for controlling cervical preneoplastic and neoplastic lesions. These include immunotherapy, vaccines targeting existing infections, and prophylactic vaccines using virus-like particles.
Area of Science:
- Oncology
- Immunology
- Virology
Background:
- Cervical cancer is a significant global health concern, often caused by persistent human papillomavirus (HPV) infections.
- Preneoplastic and neoplastic lesions of the uterine cervix are strongly associated with HPV.
- Current HPV management strategies focus on prevention and treatment of HPV-related conditions.
Purpose of the Study:
- To outline three distinct vaccine strategies for the control of HPV-associated cervical preneoplastic and neoplastic lesions.
- To evaluate the potential efficacy of different vaccine approaches targeting HPV.
- To identify the immunological responses required for effective HPV vaccine strategies.
Main Methods:
- Strategy 1: Immunotherapy targeting nonstructural HPV proteins (E6 and E7) expressed in cervical cancer cells.
- Strategy 2: Vaccines targeting early viral proteins in infected anogenital epithelial stem cells to address existing infections and early lesions.
- Strategy 3: Prophylactic vaccines utilizing genetically engineered virus-like particles (VLPs) to induce neutralizing antibodies and prevent HPV infection.
Main Results:
- All three strategies are predicted to be effective in controlling HPV-associated cervical lesions.
- Strategies 1 and 2 require the induction of cytotoxic T-cell (CTL) mediated immune responses.
- Strategy 3 aims to prevent HPV infection through antibody-mediated neutralization.
Conclusions:
- Multiple vaccine-based approaches hold potential for managing and preventing HPV-related cervical diseases.
- The choice of vaccine strategy influences the required immune response, with immunotherapy and early lesion vaccines necessitating CTL responses.
- Prophylactic vaccines offer a preventative measure against HPV infection through antibody induction.